The Chromatin Reader ZMYND8 Regulates Igh Enhancers to Promote Immunoglobulin Class Switch Recombination.

TitleThe Chromatin Reader ZMYND8 Regulates Igh Enhancers to Promote Immunoglobulin Class Switch Recombination.
Publication TypeJournal Article
Year of Publication2018
AuthorsDelgado-Benito V, Rosen DB, Wang Q, Gazumyan A, Pai JA, Oliveira TY, Sundaravinayagam D, Zhang W, Andreani M, Keller L, Kieffer-Kwon K-R, Pękowska A, Jung S, Driesner M, Subbotin RI, Casellas R, Chait BT, Nussenzweig MC, Di Virgilio M
JournalMol Cell
Volume72
Issue4
Pagination636-649.e8
Date Published2018 11 15
ISSN1097-4164
KeywordsAnimals, B-Lymphocytes, Cell Line, Chromatin, Chromatin Assembly and Disassembly, Cytidine Deaminase, DNA, Enhancer Elements, Genetic, Gene Rearrangement, Humans, Immunoglobulin Class Switching, Immunoglobulin Heavy Chains, Mice, Mice, Inbred C57BL, MYND Domains, Promoter Regions, Genetic, Regulatory Sequences, Nucleic Acid, Somatic Hypermutation, Immunoglobulin, Tumor Suppressor Proteins
Abstract

Class switch recombination (CSR) is a DNA recombination reaction that diversifies the effector component of antibody responses. CSR is initiated by activation-induced cytidine deaminase (AID), which targets transcriptionally active immunoglobulin heavy chain (Igh) switch donor and acceptor DNA. The 3' Igh super-enhancer, 3' regulatory region (3'RR), is essential for acceptor region transcription, but how this function is regulated is unknown. Here, we identify the chromatin reader ZMYND8 as an essential regulator of the 3'RR. In B cells, ZMYND8 binds promoters and super-enhancers, including the Igh enhancers. ZMYND8 controls the 3'RR activity by modulating the enhancer transcriptional status. In its absence, there is increased 3'RR polymerase loading and decreased acceptor region transcription and CSR. In addition to CSR, ZMYND8 deficiency impairs somatic hypermutation (SHM) of Igh, which is also dependent on the 3'RR. Thus, ZMYND8 controls Igh diversification in mature B lymphocytes by regulating the activity of the 3' Igh super-enhancer.

DOI10.1016/j.molcel.2018.08.042
Alternate JournalMol. Cell
PubMed ID30293785
PubMed Central IDPMC6242708
Grant ListR01 AI037526 / AI / NIAID NIH HHS / United States
P41 GM103314 / GM / NIGMS NIH HHS / United States
R37 AI037526 / AI / NIAID NIH HHS / United States
T32 GM007739 / GM / NIGMS NIH HHS / United States
P41 GM109824 / GM / NIGMS NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States